Sexual Dysfunction

Flibanserin Approved… Women’s Health and Safety Ignored!

By Shaniqua Seth | Aug 19, 2015 | Comments Off on Flibanserin Approved… Women’s Health and Safety Ignored!

I’m disappointed and you should be too. Today, the Food & Drug Administration announced the approval of flibanserin, a proposed treatment for “hypoactive sexual desire disorder” in women. Since its founding, the National Women’s Health Network has ensured that the voices of women consumers are heard and respected. Today, clever marketing trumped decades worth of consumer protections that the Network has worked hard to secure and maintain.

Sexism and the Pink Pill

By Cindy Pearson | Aug 13, 2015 | Comments Off on Sexism and the Pink Pill

I’m sure you’ve turned on the television and seen ads marketing drugs for male sexual dysfunction like Viagra. The pharmaceutical industry spends millions marketing these drugs for men, but have yet to come up with a safe and effective drug…

Sex Drugs for Women: Myths and Marketing Messages

By Coco Jervis | Aug 7, 2015 | Comments Off on Sex Drugs for Women: Myths and Marketing Messages

Learn about 5 common myths surrounding sex drugs like Addyi and Viagra as well as the FDA’s approach to this issue.

The FDA’s Hesitation to Approve ‘Female Sexual Dysfunction’ Drugs Isn’t About Sexism

By Coco Jervis | Mar 27, 2015 | Comments Off on The FDA’s Hesitation to Approve ‘Female Sexual Dysfunction’ Drugs Isn’t About Sexism

The cultural impact and huge profitability of male-targeted impotence drugs has prompted a rapidly accelerating race to create similar drug treatments for women. Despite more than a decade of research and millions of dollars spent on development, the Food and Drug Administration (FDA) has yet to approve a single drug treatment for cis women dealing with so-called female sexual dysfunction (FSD).

FDA Scientific Workshop – Female Sexual Interest/Arousal Disorder

By Cindy Pearson | Oct 28, 2014 | Comments Off on FDA Scientific Workshop – Female Sexual Interest/Arousal Disorder

Food and Drug Administration Scientific Workshop on Female Sexual Interest/Arousal Disorder